The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Case report: unusual toxicity after treatment with brexu-cel
Jacopo Mariotti, MD, Humanitas Research Hospital, Milan, Italy, discusses a poster presented at the 5th European CAR T-cell Meeting, which focused on a patient with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who experienced unusual toxicity after treatment with brexucabtagene autoleucel (brexu-cel). Dr Mariotti explains some of the unusual toxicities experienced by the patient, including unexpected neurological symptoms and maculopapular rash. To conclude, Dr Mariotti discusses how these toxicities were managed, and further highlights findings from a bone marrow biopsy conducted after treatment. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
